The estimated Net Worth of Davey Scoon is at least 715 千$ dollars as of 21 May 2015. Mr. Scoon owns over 5,709 units of AMAG Pharmaceuticals stock worth over 272,925$ and over the last 18 years he sold AMAG stock worth over 184,857$. In addition, he makes 257,486$ as Independent Director at AMAG Pharmaceuticals.
Davey has made over 1 trades of the AMAG Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,709 units of AMAG stock worth 184,857$ on 21 May 2015.
The largest trade he's ever made was selling 5,709 units of AMAG Pharmaceuticals stock on 21 May 2015 worth over 184,857$. On average, Davey trades about 190 units every 0 days since 2006. As of 21 May 2015 he still owns at least 10,917 units of AMAG Pharmaceuticals stock.
You can see the complete history of Mr. Scoon stock trades at the bottom of the page.
Davey S. Scoon CPA serves as Independent Director of the Company. Mr. Scoon served as Chief Administrative and Financial Officer of Tom's of Maine, a company that manufactures natural care products, from 2003 to 2005. From 2001 to 2003, Mr. Scoon served as Chief Financial and Administrative Officer for Sun Life Financial U.S., and from 1999 to 2001, Mr. Scoon served as Vice President and Chief Financial Officer for Sun Life Financial U.S. From 1985 to 1999, Mr. Scoon was employed by Liberty Funds Group of Boston (formerly Colonial Management) in various capacities, including Chief Financial Officer and Chief Operating Officer. Since 2012, Mr. Scoon has been a member of the Board of Directors and the Chairman of the Audit Committee of Albireo Pharma, Inc. (formerly known as Biodel Inc.), a public biopharmaceutical company. Mr. Scoon has been a director of Allianz Funds, an investment company registered under the Investment Company Act of 1940, since 2006, where he also served as Chairman of the Board of Trustees until January 2019. Mr. Scoon was also a member of the Board of Directors and the Audit Committee of Orthofix International, N.V., a medical device company, from 2011 to June 2015. Mr. Scoon was an Adjunct Professor at the University of Wisconsin-Madison from 2011 to 2018. Mr. Scoon holds a B.B.A. from the University of Wisconsin and an M.B.A. from Harvard Business School and is a Certified Public Accountant. The Board believes that Mr. Scoon's extensive financial, accounting and operational experience gained through the various executive and board positions he has held over the past 30 years provides the Board with valuable and highly specialized expertise and advice, particularly in Mr. Scoon's role as the Chair of the Audit Committee.
As the Independent Director of AMAG Pharmaceuticals, the total compensation of Davey Scoon at AMAG Pharmaceuticals is 257,486$. There are 5 executives at AMAG Pharmaceuticals getting paid more, with Joseph Vittiglio having the highest compensation of 1,411,860$.
Davey Scoon is 73, he's been the Independent Director of AMAG Pharmaceuticals since 2006. There are no older and 12 younger executives at AMAG Pharmaceuticals.
Davey's mailing address filed with the SEC is C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON, MA, 02109.
Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over 162,079,471$ worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth 65,172,892$ . The most active insiders traders include Capital, Llc Armistice Capi...、Capital Partners Gp, L.L.C....、Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of 2,148,850$. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth 59,572,300$.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
AMAG Pharmaceuticals executives and other stock owners filed with the SEC include: